UroGen Pharma (URGN) to Release Earnings on Monday

UroGen Pharma (NASDAQ:URGN - Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Monday, May 13th. Analysts expect UroGen Pharma to post earnings of ($0.93) per share for the quarter. Investors interested in participating in the company's conference call can do so using this link.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.05). The business had revenue of $23.53 million during the quarter, compared to analyst estimates of $22.30 million. On average, analysts expect UroGen Pharma to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

UroGen Pharma Stock Down 3.1 %

Shares of NASDAQ:URGN traded down $0.45 during trading on Monday, hitting $13.85. The stock had a trading volume of 397,986 shares, compared to its average volume of 326,589. UroGen Pharma has a 12 month low of $8.69 and a 12 month high of $24.13. The company has a market capitalization of $324.78 million, a PE ratio of -3.71 and a beta of 1.09. The firm's fifty day moving average is $15.22 and its 200 day moving average is $14.70.

Insider Buying and Selling

In other UroGen Pharma news, insider Mark Schoenberg sold 12,000 shares of the business's stock in a transaction on Monday, March 18th. The stock was sold at an average price of $14.05, for a total value of $168,600.00. Following the sale, the insider now directly owns 139,437 shares of the company's stock, valued at $1,959,089.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.13% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on URGN. HC Wainwright reissued a "buy" rating and set a $54.00 price objective on shares of UroGen Pharma in a research report on Monday. Oppenheimer lowered their price target on shares of UroGen Pharma from $35.00 to $34.00 and set an "outperform" rating for the company in a research report on Friday, March 15th.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.